Dannex Ayrton Starwin Plc manufactures and sells pharmaceutical products in Ghana.
Price History & Performance
|Historical stock prices|
|Current Share Price||GH₵0.40|
|52 Week High||GH₵0|
|52 Week Low||GH₵0|
|1 Month Change||0%|
|3 Month Change||n/a|
|1 Year Change||n/a|
|3 Year Change||n/a|
|5 Year Change||n/a|
|Change since IPO||0%|
Recent News & Updates
|DASPHARMA||GH Pharmaceuticals||GH Market|
Return vs Industry: Insufficient data to determine how DASPHARMA performed against the GH Pharmaceuticals industry.
Return vs Market: Insufficient data to determine how DASPHARMA performed against the GH Market.
Stable Share Price: Insufficient data to determine DASPHARMA's volatility over the past 3 months.
Volatility Over Time: Insufficient data to determine DASPHARMA's volatility change over the past year.
About the Company
|n/a||n/a||Daniel Kwabena Kissi||https://dasgh.com|
Dannex Ayrton Starwin Plc manufactures and sells pharmaceutical products in Ghana. The company offers a range of products in various categories, such as analgesics, hematinics, anti-tussives, dermatological products, anti-convulsing, and anti-asthmatics in form of tablets, capsules, liquids, powders, ointments, and chemicals. It provides its products under the Durol, Virol, Samalin, Teeder, Koffex, ORS, Rapinol, Asmadrin, and Milk of Magnesia names.
Dannex Ayrton Starwin Fundamentals Summary
|DASPHARMA fundamental statistics|
Is DASPHARMA overvalued?See Fair Value and valuation analysis
Earnings & Revenue
|DASPHARMA income statement (TTM)|
|Cost of Revenue||GH₵0|
Last Reported Earnings
Next Earnings Date
|Earnings per share (EPS)||0|
|Net Profit Margin||0.00%|
How did DASPHARMA perform over the long term?See historical performance and comparison
Is Dannex Ayrton Starwin undervalued compared to its fair value and its price relative to the market?
In this section, we usually try to help investors determine whether Dannex Ayrton Starwin is trading at an attractive price based on the cash flow it is expected to produce in the future. But as Dannex Ayrton Starwin has not provided consistent financial data, and the stock also has no analyst forecast or coverage, its intrinsic value cannot be reliably calculated by extrapolating past data or using analyst consensus cash flow predictions.
This is quite a rare situation as 89% of companies covered by Simply Wall St do have a valuation analysis.
How is Dannex Ayrton Starwin forecast to perform in the next 1 to 3 years based on estimates from 0 analysts?
Forecasted Pharmaceuticals & Biotech industry annual growth in earnings
In this section we usually present revenue and earnings growth projections based on the consensus estimates of professional analysts to help investors understand the company’s ability to generate profit. But as Dannex Ayrton Starwin has not provided enough past data and has no analyst forecast, its future earnings cannot be reliably calculated by extrapolating past data or using analyst predictions.
This is quite a rare situation as 97% of companies covered by SimplyWall St do have past financial data.
How has Dannex Ayrton Starwin performed over the past 5 years?
Historical Pharmaceuticals & Biotech annual earnings growth
In this section we usually display a company’s past earnings and revenues to help investors visualise the trend through time. We also gauge the company’s performance by benchmarking its returns and growth to its industry peers and the wider market. However, Dannex Ayrton Starwin has not provided sufficient past data to assess its track record.
This is quite a rare situation as 97% of companies covered by Simply Wall St do have historical data.
How is Dannex Ayrton Starwin's financial position?
In this section we usually analyse Dannex Ayrton Starwin's finance health to determine how well-positioned it is against times of financial distress, in particular, its ability to manage its cash and debt levels. Dannex Ayrton Starwin has not provided adequate balance sheet data, its financial health cannot be properly assessed as it.
This is quite a rare situation as 97% of companies covered by Simply Wall St do have financial information.
What is Dannex Ayrton Starwin current dividend yield, its reliability and sustainability?
Dividend Yield vs Market
Notable Dividend: Unable to evaluate DASPHARMA's dividend yield against the bottom 25% of dividend payers, as the company has not reported any recent payouts.
High Dividend: Unable to evaluate DASPHARMA's dividend yield against the top 25% of dividend payers, as the company has not reported any recent payouts.
Stability and Growth of Payments
Stable Dividend: Insufficient data to determine if DASPHARMA's dividends per share have been stable in the past.
Growing Dividend: Insufficient data to determine if DASPHARMA's dividend payments have been increasing.
Current Payout to Shareholders
Dividend Coverage: Insufficient data to calculate payout ratio to determine if its dividend payments are covered by earnings.
Future Payout to Shareholders
Future Dividend Coverage: No need to calculate the sustainability of DASPHARMA's dividend in 3 years as they are not forecast to pay a notable one for the GH market.
How experienced are the management team and are they aligned to shareholders interests?
Daniel Kwabena Kissi (54 yo)
Mr. Daniel Kwabena Apeagyei Kissi has been Managing Director of Ayrton Drugs Manufacturing Company Ltd. since December 01, 2012 and also it's Chief Executive Officer. He has been Chief Executive Officer an...
Who are the major shareholders and have insiders been buying or selling?
Insider Trading Volume
Insider Buying: Insufficient data to determine if insiders have bought more shares than they have sold in the past 3 months.
Dilution of Shares: Insufficient data to determine if shareholders have been diluted in the past year.
Dannex Ayrton Starwin Plc's employee growth, exchange listings and data sources
- Name: Dannex Ayrton Starwin Plc
- Ticker: DASPHARMA
- Exchange: GHSE
- Founded: NaN
- Industry: Pharmaceuticals
- Sector: Pharmaceuticals & Biotech
- Market Cap: GH₵0
- Shares outstanding: 0
- Website: https://dasgh.com
- Dannex Ayrton Starwin Plc
- No. 5 Dadeban Road
- Ring Road North
Company Analysis and Financial Data Status
|Data||Last Updated (UTC time)|
|Company Analysis||2021/10/17 17:03|
|End of Day Share Price||2021/09/20 00:00|
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.